SCHEDULE 13D/A Filed 2026-06-15 Event 2026-06-11 SEC 0001346824-26-000173 →

RA CAPITAL MANAGEMENT, L.P. → ARTIVA BIOTHERAPEUTICS, INC. ARTV

Stake: 36.60% Shares: 17,811,623 CUSIP: 04317A107 Class: Common Stock, par value $0.0001 per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 30/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: +0.0%

Filer track record (20 filings): 0% 90d win rate, +0.0% 90d edge
Net insider selling ($477,770 Code-S in ±30d)
High conviction ownership stake (36.6%)
Held by 1 tracked 13F institutional manager
Elevated short days-to-cover (6.0 DTC)
Short interest building (+19.2% vs prior settlement)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

11 transactions

6 buys · 5 sales · 0 awards/exercises

Issuer Cluster

5 13D/G filings on this issuer

4 other filings besides this one

Filer Track Record

88 filings by this filer

87 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 6.00

2,738,041 shares short · +19.2% vs prior

Institutional Consensus · 2026-06-30

Held by elite portfolio managers

1 holder · $25.26M

Viking Global

Post-Filing Returns · since 2026-06-11 on ARTV

+1 day

+6.7%

+5 days

+11.4%

+30 days

+11.6%

+60 days

—

+90 days

—

+180 days

—

Anchor price 8.00 on closest trading day on/after 2026-06-11. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-09-08	RA CAPITAL MANAGEMENT, L.P.	director, 10%+ owner	Award	13,750	$10.88	$150K
2026-07-13	RA CAPITAL MANAGEMENT, L.P.	director, 10%+ owner	Buy	6,552	$8.94	$59K
2026-07-10	RA CAPITAL MANAGEMENT, L.P.	director, 10%+ owner	Buy	15,102	$8.97	$135K
2026-06-11	RA CAPITAL MANAGEMENT, L.P.	director, 10%+ owner	Buy	548,580	$7.91	$4.34M
2026-06-10	RA CAPITAL MANAGEMENT, L.P.	director, 10%+ owner	Buy	103	$7.00	$721
2026-06-09	RA CAPITAL MANAGEMENT, L.P.	director, 10%+ owner	Buy	479,039	$6.91	$3.31M
2026-05-19	Raymon Heather	officer	Sale	3,095	$9.01	$28K
2026-05-19	Horan Christopher	officer	Sale	7,002	$9.01	$63K
2026-05-19	Bush Jennifer	officer	Sale	8,790	$9.01	$79K
2026-05-19	Banerjee Subhashis	officer	Sale	7,037	$9.01	$63K
2026-05-19	Aslan Fred	director, officer	Sale	27,116	$9.01	$244K

Other 13D/G Filings on ARTIVA BIOTHERAPEUTICS, INC.

Filed	Form	Filer	Stake	Shares
2026-07-23	SCHEDULE 13D/A	RA CAPITAL MANAGEMENT, L.P.	—	18,415,956	view →
2026-05-28	SCHEDULE 13D/A	GC Corp.	12.30%	5,999,703	view →
2026-05-18	SCHEDULE 13G	VIKING GLOBAL INVESTORS LP	—	—	view →
2026-05-13	SCHEDULE 13D/A	RA CAPITAL MANAGEMENT, L.P.	—	16,377,468	view →

Other Filings by RA CAPITAL MANAGEMENT, L.P.

Filed	Form	Issuer	Stake	Shares
2026-10-26	SCHEDULE 13G	Alector, Inc.	—	—	view →
2026-10-22	SCHEDULE 13G	Frazier Life Sciences Acquisition Corp. II	—	—	view →
2026-09-22	SCHEDULE 13G	BetterLife Pharma Inc.	—	—	view →
2026-09-21	SCHEDULE 13D/A	SIONNA THERAPEUTICS, INC.	14.30%	6,476,193	view →
2026-09-17	SCHEDULE 13D/A	TYRA BIOSCIENCES, INC.	—	14,130,492	view →
2026-09-03	SCHEDULE 13G	JATT III Acquisition Corp	—	—	view →
2026-08-17	SCHEDULE 13G	Latigo Biotherapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13D/A	SEPTERNA, INC.	—	5,525,324	view →
2026-08-11	SCHEDULE 13D/A	Wave Life Sciences, Inc.	—	34,314,406	view →
2026-08-10	SCHEDULE 13D/A	SAB Biotherapeutics, Inc.	—	9,609,852	view →
2026-07-23	SCHEDULE 13D/A	ARTIVA BIOTHERAPEUTICS, INC.	—	18,415,956	view →
2026-07-22	SCHEDULE 13D/A	Freenome, Inc.	—	15,367,270	view →
2026-07-21	SCHEDULE 13D/A	VOR BIOPHARMA INC.	—	12,937,855	view →
2026-07-20	SCHEDULE 13G	Agenus Inc.	—	—	view →
2026-07-07	SCHEDULE 13D/A	Climb Bio, Inc. CLYM	33.00%	23,249,186	view →
2026-07-02	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	4.10%	1,985,541	view →
2026-06-26	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	6.00%	2,915,742	view →
2026-06-24	SCHEDULE 13D/A	SOLID BIOSCIENCES INC. SLDB	—	12,036,126	view →
2026-06-22	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	3,654,307	view →
2026-06-18	SCHEDULE 13D	Parabilis Medicines, Inc. PBLS	23.80%	28,933,371	view →

Showing 20 of 87

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →